Abstract

Dopaminergic neurons of the substantia nigra are selectively vulnerable to mitochondrial dysfunction, which is hypothesized to be an early and fundamental pathogenic mechanism in Parkinson’s disease (PD). Mitochondrial function depends on the successful import of nuclear-encoded proteins, many of which are transported through the TOM20–TOM22 outer mitochondrial membrane import receptor machinery. Recent data suggests that post-translational modifications of α-synuclein promote its interaction with TOM20 at the outer mitochondrial membrane and thereby inhibit normal protein import, leading to dysfunction, and death of dopaminergic neurons. As such, preservation of mitochondrial import in the face of α-synuclein accumulation might be a strategy to prevent dopaminergic neurodegeneration, however, this is difficult to assess using current in vivo models of PD. To this end, we established an exogenous co-expression system, utilizing AAV2 vectors to overexpress human α-synuclein and TOM20, individually or together, in the adult Lewis rat substantia nigra to assess whether TOM20 overexpression attenuates α-synuclein-induced dopaminergic neurodegeneration. Twelve weeks after viral injection, we observed that AAV2-TOM20 expression was sufficient to prevent loss of nigral dopaminergic neurons caused by AAV2-αSyn overexpression. The observed TOM20-mediated dopaminergic neuron preservation appeared to be due, in part, to the rescued expression (and presumed import) of nuclear-encoded mitochondrial electron transport chain proteins that were inhibited by α-synuclein overexpression. In addition, TOM20 overexpression rescued the expression of the chaperone protein GRP75/mtHSP70/mortalin, a stress-response protein involved in α-synuclein-induced injury. Collectively, these data indicate that TOM20 expression prevents α-synuclein-induced mitochondrial dysfunction, which is sufficient to rescue dopaminergic neurons in the adult rat brain.

Highlights

  • Among the characteristic molecular pathologies of Parkinson’s disease (PD) is the accumulation of α-synuclein within nigrostriatal dopaminergic neurons

  • Animals that received AAV2-αSyn/GFP or AAV2-TOM20/αSyn injections displayed a robust expression of human α-synuclein protein with the neurons of the substantia nigra, which was absent in the AAV2-TOM20/GFP control group (Fig. 2a, b)

  • Midbrain tissue from animals expressing human AAV2-TOM20/αSyn was incubated with proteinase K, which revealed a fraction of insoluble αsynuclein protein aggregates following 12 weeks of viral vector incubation within the ipsilateral injection hemisphere (Fig. 2c)

Read more

Summary

Introduction

Among the characteristic molecular pathologies of Parkinson’s disease (PD) is the accumulation of α-synuclein within nigrostriatal dopaminergic neurons. We described a mechanism by which α-synuclein directly interacts with the mitochondrial translocase of the outer membrane (TOM) receptor, TOM20, and reduces import of proteins which contain an N-terminal mitochondrial targeting signal (MTS)[1]. These data showed that oligomeric, and post-translationally modified α-synuclein (oxidized, or dopamine modified), but not monomeric or nitrated α-synuclein, bind to TOM20 and prevent its association with TOM22, a key step in formation of the TOM complex that is necessary for protein import[1].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call